CLOSEOUT LETTER
Spinal Elements, Inc
- Recipient:
- Spinal Elements, Inc
United States
- Issuing Office:
United States
Office of Medical Devices and Radiological Health Operations | |
UNITED PARCEL SERVICE
SIGNATURE REQUIRED
11/01/2017
CMS 421804 FY2017
Jason D. Blain
President
Spinal Elements, Inc.
3115 Melrose Drive, Suite 200
Carlsbad, California 92010
Dear Mr. Blain:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter # 21-14 dated June 12, 2014. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Kelly D. Sheppard
Director, Compliance Branch